The Children’s Tumor Foundation is an Associated Partner of the European-based Innovative Medicines Initiative
The Innovative Medicines Initiative (IMI), a jointly funded partnership between the European Union (EU) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), will soon issue a call for an integrated research platform enabling patient-centric drug development.
The Children’s Tumor Foundation (CTF), the largest non-governmental funder of neurofibromatosis (NF) research, and PLOS ONE, a leading peer-reviewed scientific journal, are pleased to announce the successful completion of the first funding cycle of the Drug Discovery Initiative Registered Report (DDIRR) 2017 Awards, a funder-publisher partnership integrating the Registered Reports model into the grant application process.
Children’s Tumor Foundation Synodos Review Committee Leader Anna Barker, PhD, was presented a Special Recognition Award at the Annual Meeting of the American Association for Cancer Research (AACR). This award was presented to individuals whose work has made extraordinary contributions to accelerate the prevention and cure of all cancers through research, education, communication, and collaboration.
By Salvatore La Rosa
On Feb 29, 2008, EURORDIS, a European rare disease organization, sponsored the first Rare Disease Day in Europe. Then the United States joined the first global observance the following year, along with 23 other countries. This year I was invited to participate at the Rare Disease Day at the National Institutes of Health (NIH), an event that aims to bring together “Patients and Researchers – Partners for Life,” as their slogan has always been.
The Children’s Tumor Foundation’s commitment to collaboration, open data and transparency is reinforced with a partnership with global technology company Digital Science on a new platform for next-generation research and discovery called Dimensions. This groundbreaking research information database aims to transform scholarly search by linking publications, grants, policy, data, and metrics for the first time.